Organogenesis (NASDAQ:ORGO) Coverage Initiated at Lake Street Capital

Lake Street Capital assumed coverage on shares of Organogenesis (NASDAQ:ORGO) in a research note published on Friday morning, Marketbeat.com reports. The firm issued a buy rating and a $5.00 price objective on the stock.

Separately, Cantor Fitzgerald reaffirmed an overweight rating and set a $5.00 price target on shares of Organogenesis in a report on Friday, March 1st.

Organogenesis Stock Down 3.6 %

Shares of NASDAQ:ORGO opened at $2.70 on Friday. Organogenesis has a fifty-two week low of $1.96 and a fifty-two week high of $4.70. The firm’s 50 day moving average price is $2.62 and its 200 day moving average price is $3.11. The company has a quick ratio of 2.41, a current ratio of 2.74 and a debt-to-equity ratio of 0.22. The stock has a market cap of $357.94 million, a price-to-earnings ratio of 67.50 and a beta of 1.66.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. The business had revenue of $109.98 million for the quarter, compared to analyst estimates of $100.44 million. Organogenesis had a net margin of 1.34% and a return on equity of 2.11%. During the same period last year, the business earned ($0.02) EPS. As a group, equities research analysts predict that Organogenesis will post -0.05 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ORGO. Tower Research Capital LLC TRC raised its stake in Organogenesis by 94.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,663 shares of the company’s stock worth $27,000 after acquiring an additional 3,235 shares in the last quarter. Victory Capital Management Inc. acquired a new stake in shares of Organogenesis during the fourth quarter worth about $43,000. Palumbo Wealth Management LLC purchased a new stake in shares of Organogenesis in the 4th quarter valued at about $46,000. Barclays PLC boosted its position in shares of Organogenesis by 80.6% in the 3rd quarter. Barclays PLC now owns 25,276 shares of the company’s stock valued at $80,000 after purchasing an additional 11,284 shares during the period. Finally, Capital Square LLC grew its stake in Organogenesis by 23.8% during the 4th quarter. Capital Square LLC now owns 20,450 shares of the company’s stock worth $84,000 after buying an additional 3,930 shares during the last quarter. Institutional investors and hedge funds own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.